Maxcyte (MXCT) Accounts Payables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accounts Payables data on file, last reported at $1.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.2 million, down 47.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 47.52% YoY), and the FY2025 annual result was $1.4 million, up 3.17% from the prior year.
• Accounts Payables fell to $1.2 million in Q1 2026 per MXCT's latest filing, from $1.4 million in the prior quarter.
• Over five years, Accounts Payables peaked at $4.4 million in Q1 2022 and troughed at $292000.0 in Q4 2022.
• A 5-year average of $1.7 million and a median of $1.4 million in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables plunged 83.96% in 2022, then soared 317.6% in 2024.
• A 5-year view of Accounts Payables shows it stood at $292000.0 in 2022, then soared by 154.45% to $743000.0 in 2023, then soared by 82.77% to $1.4 million in 2024, then advanced by 3.17% to $1.4 million in 2025, then decreased by 14.63% to $1.2 million in 2026.
• Business Quant data shows MXCT's Accounts Payables at $1.2 million in Q1 2026, $1.4 million in Q4 2025, and $1.3 million in Q3 2025.